Skip to main content
. 2017 Jan 27;8(9):15393–15398. doi: 10.18632/oncotarget.14871

Figure 3. Knockdown of CASC9 reverses chemoresistance in BGC823/DR and SGC7901/DR cells.

Figure 3

(A) IC50 of BGC823/DR and SGC7901/DR cells to paclitaxel after CASC9 knockdown. (B) IC50 of BGC823/DR and SGC7901/DR cells to adriamycin after CASC9 knockdown. (C) The expression of MDR1 protein in BGC823/DR and SGC7901/DR cells after CASC9 knockdown.